Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamidronate for Bone Loss Prevention in Pediatric HCT
NCT02074631Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- Feb 2015
- Primary completion
- Oct 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pamidronate in osteopenia and osteoporosis (2 arms), sponsored by Masonic Cancer Center. Primary endpoint: Lumbar Spine Bone Mineral Content at 1 year. Started Feb 2015; status: completed.
02
Drugs
pamidronate
03
Conditions
osteopeniaosteoporosis
Beyond the preview
Go deeper on NCT02074631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02074631.